Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

<p>Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra’s purchase of Acer’s secured debt in capital efficient structure Zevra to assume commercialization efforts of OLPRUVA™, recently approved for the treatment of urea cycle disorders (UCDs) FDA-approved commercial asset expected to increase and diversify Zevra’s revenues OLPRUVA™ commercial operations provide [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/zevra-therapeutics-to-acquire-acer-therapeutics-expanding-its-rare-disease-portfolio-and-adding-commercial-product/">Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>